Edition:
United Kingdom

MacroGenics Inc (MGNX.OQ)

MGNX.OQ on NASDAQ Stock Exchange Global Select Market

18.71USD
11 Dec 2017
Change (% chg)

$-0.79 (-4.05%)
Prev Close
$19.50
Open
$19.60
Day's High
$19.64
Day's Low
$18.66
Volume
77,380
Avg. Vol
94,110
52-wk High
$26.99
52-wk Low
$14.36

Chart for

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology... (more)

Overall

Beta: 2.78
Market Cap(Mil.): $659.43
Shares Outstanding(Mil.): 36.80
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Macrogenics- increased number of directors that constitute board from eight to nine ​

* Macrogenics- increased number of directors that constitute board from eight to nine after approving appointment of Jay Siegel on Nov 13 - SEC filing ​ Source text: (http://bit.ly/2A2CHjE) Further company coverage:

16 Nov 2017

BRIEF-Macrogenics names Jay Siegel to its board of directors

* Macrogenics names Jay Siegel to its board of directors Source text for Eikon: Further company coverage:

15 Nov 2017

BRIEF-Macrogenics Posts Q3 loss of $1.28 per share

* Macrogenics provides update on corporate progress and third quarter 2017 financial results

08 Nov 2017

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

25 Oct 2017

BRIEF-Macrogenics advances two clinical DART molecules

* Macrogenics advances two first-in-class clinical DART molecules

05 Sep 2017

BRIEF-Macrogenics announces termination of duvortuxizumab collaboration

* Macrogenics announces termination of duvortuxizumab collaboration and license agreement with Janssen

31 Aug 2017

BRIEF-MacroGenics Q2 net loss per share $1.14

* MacroGenics provides update on corporate progress and second quarter 2017 financial results

02 Aug 2017

BRIEF-Boxer Capital reports 5.5 pct passive stake in Macrogenics

* Boxer Capital, Llc reports 5.5 percent passive stake in Macrogenics Inc as of may 31, 2017 -sec filing Source text - http://bit.ly/2sVCckL Further company coverage:

12 Jun 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF240.60 --
Roche Holding Ltd. (RO.S) CHF243.20 --
Amgen, Inc. (AMGN.OQ) $176.83 --
Xencor Inc (XNCR.OQ) $21.62 -0.73

Earnings vs. Estimates